Agilon Health Inc Financials
Agilon Health Inc (AGL) reported $5.9B in revenue for fiscal year 2025, down 2.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A low-capital but loss-heavy model is shrinking agilon health’s equity cushion faster than debt is building.
From FY2023 to FY2025, long-term debt fell from$32.3M to$15.8M even as equity dropped from$661.8M to$126.7M and the current ratio slid from 1.5x to 1.0x, which points to strain coming mainly from recurring operating losses and heavier non-debt liabilities rather than from borrowing. Because debt stayed modest, return on equity at-308.8% is largely a denominator story: the equity base has become small enough that each new loss distorts the ratio sharply.
The business is not capex-hungry: FY2025 capital spending was only
FY2024 looked closer to a steadier loss profile, but FY2025 showed how thin the margin structure still is as revenue slipped
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Agilon Health Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Agilon Health Inc has an operating margin of -7.8%, meaning the company loses $8 on every $100 of revenue. This results in a profitability score of 30/100. This is down from -4.8% the prior year.
Agilon Health Inc's revenue declined 2.1% year-over-year, from $6.1B to $5.9B. This contraction results in a growth score of 78/100.
Agilon Health Inc carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
Agilon Health Inc's current ratio of 1.02 is below the typical benchmark, resulting in a score of 19/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Agilon Health Inc's operations used $105.8M of cash, and capex of $13.2M added to the outflow, for a free cash flow shortfall of $119.0M. This results in a cash flow score of 24/100.
Agilon Health Inc posts a -308.8% return on equity (ROE), meaning it loses $309 for every $100 of shareholders' equity. This results in a returns score of 11/100. This is down from -55.2% the prior year.
Agilon Health Inc scores 2.13, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Agilon Health Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Agilon Health Inc reported a net loss of $391.3M while operations used $105.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Agilon Health Inc reported an operating loss of $463.2M against $6.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Agilon Health Inc generated $5.9B in revenue in fiscal year 2025. This represents a decrease of 2.1% from the prior year.
Agilon Health Inc's EBITDA was -$434.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 62.4% from the prior year.
Agilon Health Inc reported -$391.3M in net income in fiscal year 2025. This represents a decrease of 50.4% from the prior year.
Cash & Balance Sheet
Agilon Health Inc recorded an outflow of $119.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 67.5% from the prior year.
Agilon Health Inc held $173.7M in cash against $15.8M in long-term debt as of fiscal year 2025, with $1.1B of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
Agilon Health Inc's operating margin was -7.8% in fiscal year 2025, reflecting core business profitability. This is down 3.0 percentage points from the prior year.
Agilon Health Inc's net profit margin was -6.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 2.3 percentage points from the prior year.
Agilon Health Inc's ROE was -308.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 253.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Agilon Health Inc repurchased no shares in fiscal year 2025.
Agilon Health Inc invested $13.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.1% from the prior year.
Not reported for fiscal year 2025.
AGL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9B | $5.9B-2.1% | $6.1B+40.4% | $4.3B+80.7% | $2.4B+57.0% | $1.5B+24.9% | $1.2B+53.4% | $794.4M |
| SG&A Expenses | $259.0M | $238.5M-11.3% | $268.9M-5.9% | $285.8M+37.5% | $207.8M-51.4% | $427.5M+211.4% | $137.3M+11.8% | $122.8M |
| Operating Income | -$309.3M | -$463.2M-58.6% | -$292.1M-25.8% | -$232.1M-120.3% | -$105.4M+71.7% | -$372.2M-556.8% | -$56.7M+46.8% | -$106.6M |
| Interest Expense | $7.0M | $6.6M+7.5% | $6.2M-7.2% | $6.7M+48.5% | $4.5M-27.0% | $6.1M-24.4% | $8.1M-10.3% | $9.1M |
| Income Tax | $646K | $1.3M-13.8% | $1.5M+83.4% | $791K-51.8% | $1.6M+85.1% | $886K+2.4% | $865K+472.8% | -$232K |
| Net Income | -$232.2M | -$391.3M-50.4% | -$260.2M+0.9% | -$262.6M-146.4% | -$106.6M+73.8% | -$406.5M-576.9% | -$60.1M+78.7% | -$282.6M |
| EPS (Diluted) | — | -$0.98 | -$0.61-27.1% | -$0.48-118.2% | -$0.22+78.6% | -$1.03-415.0% | -$0.20 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AGL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B-26.7% | $1.7B-0.4% | $1.7B+2.6% | $1.7B+7.0% | $1.6B+255.4% | $446.4M | N/A |
| Current Assets | $1.1B-24.8% | $1.5B-1.5% | $1.5B+2.0% | $1.5B+6.1% | $1.4B+364.7% | $294.2M | N/A |
| Cash & Equivalents | $173.7M-7.7% | $188.2M+75.0% | $107.6M-76.9% | $465.3M-55.3% | $1.0B+873.9% | $106.8M-23.3% | $139.2M |
| Goodwill | $0-100.0% | $24.1M0.0% | $24.1M+860.3% | $2.5M-94.0% | $41.5M0.0% | $41.5M | N/A |
| Total Liabilities | $1.1B-9.4% | $1.3B+17.0% | $1.1B+64.4% | $656.9M+32.8% | $494.7M-32.3% | $731.1M | N/A |
| Current Liabilities | $1.1B-6.6% | $1.2B+17.9% | $977.2M+82.6% | $535.1M+49.9% | $357.0M+33.8% | $266.8M | N/A |
| Long-Term Debt | $15.8M-54.9% | $34.9M+8.0% | $32.3M-16.0% | $38.5M-11.3% | $43.4M-32.9% | $64.7M | N/A |
| Total Equity | $126.7M-73.1% | $471.0M-28.8% | $661.8M-36.4% | $1.0B-4.6% | $1.1B+483.5% | -$284.7M-22.7% | -$232.0M |
| Retained Earnings | -$2.0B-24.7% | -$1.6B-19.6% | -$1.3B-24.7% | -$1.1B-11.1% | -$957.7M-73.7% | -$551.2M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
AGL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$72.3M | -$105.8M-83.1% | -$57.8M+63.0% | -$156.2M-19.4% | -$130.8M+11.7% | -$148.2M-178.5% | -$53.2M+48.8% | -$103.9M |
| Capital Expenditures | $12.7M | $13.2M-0.1% | $13.3M-16.3% | $15.8M+2.6% | $15.4M+135.0% | $6.6M+269.8% | $1.8M-38.6% | $2.9M |
| Free Cash Flow | -$85.0M | -$119.0M-67.5% | -$71.0M+58.7% | -$172.0M-17.6% | -$146.2M+5.5% | -$154.7M-181.4% | -$55.0M+48.5% | -$106.8M |
| Investing Cash Flow | $80.4M | $88.6M-36.7% | $139.9M+417.8% | -$44.0M+90.1% | -$444.4M-391.0% | -$90.5M-510.2% | $22.1M+536.1% | -$5.1M |
| Financing Cash Flow | -$769K | -$3.0M-15.9% | -$2.6M+98.7% | -$193.1M-788.4% | $28.1M-97.6% | $1.2B+4588.6% | $24.6M-86.0% | $176.3M |
| Share Buybacks | N/A | $0 | $0-100.0% | $200.0M | $0 | $0-100.0% | $6.7M | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AGL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -7.8%-3.0pp | -4.8%+0.6pp | -5.4%-1.0pp | -4.4%+20.1pp | -24.5%-19.8pp | -4.7%+8.8pp | -13.4% |
| Net Margin | -6.6%-2.3pp | -4.3%+1.8pp | -6.1%-1.6pp | -4.5%+22.3pp | -26.7%-21.8pp | -4.9%+30.6pp | -35.6% |
| Return on Equity | -308.8%-253.5pp | -55.2%-15.6pp | -39.7%-29.4pp | -10.2%+27.0pp | -37.2% | N/A | N/A |
| Return on Assets | -30.8%-15.8pp | -15.0%+0.1pp | -15.1%-8.8pp | -6.3%+19.3pp | -25.6%-12.2pp | -13.5% | N/A |
| Current Ratio | 1.02-0.2x | 1.27-0.2x | 1.51-1.2x | 2.71-1.1x | 3.83+2.7x | 1.10 | N/A |
| Debt-to-Equity | 0.12+0.1x | 0.070.0x | 0.050.0x | 0.040.0x | 0.04 | N/A | N/A |
| FCF Margin | -2.0%-0.8pp | -1.2%+2.8pp | -4.0%+2.1pp | -6.1%+4.0pp | -10.2%-5.7pp | -4.5%+8.9pp | -13.4% |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Where Agilon Health Inc Ranks
Frequently Asked Questions
What is Agilon Health Inc's annual revenue?
Agilon Health Inc (AGL) reported $5.9B in total revenue for fiscal year 2025. This represents a -2.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Agilon Health Inc's revenue growing?
Agilon Health Inc (AGL) revenue declined by 2.1% year-over-year, from $6.1B to $5.9B in fiscal year 2025.
Is Agilon Health Inc profitable?
No, Agilon Health Inc (AGL) reported a net income of -$391.3M in fiscal year 2025, with a net profit margin of -6.6%.
What is Agilon Health Inc's EBITDA?
Agilon Health Inc (AGL) had EBITDA of -$434.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Agilon Health Inc have?
As of fiscal year 2025, Agilon Health Inc (AGL) had $173.7M in cash and equivalents against $15.8M in long-term debt.
What is Agilon Health Inc's operating margin?
Agilon Health Inc (AGL) had an operating margin of -7.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Agilon Health Inc's net profit margin?
Agilon Health Inc (AGL) had a net profit margin of -6.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Agilon Health Inc's return on equity (ROE)?
Agilon Health Inc (AGL) has a return on equity of -308.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Agilon Health Inc's free cash flow?
Agilon Health Inc (AGL) recorded an outflow of $119.0M in free cash flow during fiscal year 2025. This represents a -67.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Agilon Health Inc's operating cash flow?
Agilon Health Inc (AGL) recorded an outflow of $105.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Agilon Health Inc's total assets?
Agilon Health Inc (AGL) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Agilon Health Inc's capital expenditures?
Agilon Health Inc (AGL) invested $13.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Agilon Health Inc's current ratio?
Agilon Health Inc (AGL) had a current ratio of 1.02 as of fiscal year 2025, which is considered adequate.
What is Agilon Health Inc's debt-to-equity ratio?
Agilon Health Inc (AGL) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Agilon Health Inc's return on assets (ROA)?
Agilon Health Inc (AGL) had a return on assets of -30.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Agilon Health Inc's cash runway?
Based on fiscal year 2025 data, Agilon Health Inc (AGL) had $173.7M in cash against an annual operating cash burn of $105.8M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Agilon Health Inc's Altman Z-Score?
Agilon Health Inc (AGL) has an Altman Z-Score of 2.13, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Agilon Health Inc's Piotroski F-Score?
Agilon Health Inc (AGL) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Agilon Health Inc's earnings high quality?
Agilon Health Inc (AGL) reported a net loss of $391.3M while operations used $105.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Agilon Health Inc cover its interest payments?
Agilon Health Inc (AGL) reported an operating loss of $463.2M against $6.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Agilon Health Inc?
Agilon Health Inc (AGL) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.